Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Strong Trading Volume – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw unusually-high trading volume on Monday . Approximately 4,632,423 shares changed hands during mid-day trading, a decline of 29% from the previous session’s volume of 6,480,514 shares.The stock last traded at $7.78 and had previously closed at $6.95.

Analysts Set New Price Targets

Several equities research analysts have weighed in on RXRX shares. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Jefferies Financial Group dropped their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Finally, Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Trading Down 4.3 %

The firm has a market cap of $2.04 billion, a PE ratio of -4.65 and a beta of 0.85. The company’s 50 day moving average price is $6.77 and its 200 day moving average price is $7.23. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. During the same period last year, the business posted ($0.43) EPS. Recursion Pharmaceuticals’s revenue was up 147.6% on a year-over-year basis. As a group, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $6.32, for a total transaction of $94,800.00. Following the sale, the chief financial officer now owns 1,426,506 shares in the company, valued at approximately $9,015,517.92. This represents a 1.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Tina Marriott sold 6,000 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $7.00, for a total transaction of $42,000.00. Following the completion of the transaction, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,647,966. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 107,788 shares of company stock worth $724,691 over the last ninety days. 15.75% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RXRX. ARK Investment Management LLC boosted its position in shares of Recursion Pharmaceuticals by 16.4% in the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after acquiring an additional 4,626,268 shares during the last quarter. State Street Corp raised its position in shares of Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after buying an additional 4,120,685 shares during the period. Baillie Gifford & Co. boosted its holdings in Recursion Pharmaceuticals by 10.5% in the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock valued at $199,425,000 after acquiring an additional 2,522,132 shares during the last quarter. Lingotto Investment Management LLP increased its stake in Recursion Pharmaceuticals by 69.0% during the second quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock worth $27,563,000 after acquiring an additional 1,500,000 shares during the last quarter. Finally, Ghisallo Capital Management LLC purchased a new position in shares of Recursion Pharmaceuticals in the 2nd quarter worth about $8,250,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.